Work

Cellular Localization Of Inflammatory Signaling As A Determinant Of Tumor-Immune Biology

Year: 2001
Type: article
Abstract: Immune therapies have significantly improved outcomes for cancer patients with\npoor prognosis, but mechanisms that underlie response or resistance to therapy remain\nelusive. Inflammatory cytokines such as interferon-gamma (IFNG) augment immune\nfunction yet also promote T cell exhaustion through inhibitory ligands such as PDL1. How\nthese opposing effects are integrated in the tumor microenvironment is unclear. We show\nthat while inhibiting tumor IFNG signaling decreases interferon-stimulated genes (ISGs)\nin cancer cells, it increases ISGs in immune cells by enhancing IFNG produced by\nexhausted T cells (TEX). In tumors with favorable antigenicity, these TEX mediate rejection.\nIn tumors with neoantigen or MHC-I loss, TEX instead utilize IFNG to drive maturation of\ninnate immune cells, promoting tumor clearance. Thus, interferon signaling in cancer cells\nand immune cells oppose each other to establish a regulatory relationship that limits both\nadaptive and innate immune killing. In melanoma and lung cancer patients, perturbation\nof this relationship is associated with response to immune checkpoint blockade\nindependent of tumor mutational burden.\nIn addition to these suppressive mechanisms, tumor infiltration and antigen loss\nare common mechanisms that limit effectiveness of T cell responses in solid tumors, in\nparticular chimeric antigen (CAR) T cells. Delivery of pattern recognition receptor agonists\nis one strategy to improve immune infiltration and prime adaptive immunity; however,\ntargeting these agonists to immune cells is challenging, and off-target signaling in cancer\ncells can be detrimental as described above. Here, we engineer murine CAR-T cells to\ndeliver RN7SL1, an endogenous RNA that activates RIG-I/MDA5-dependent interferon\nsignaling. RN7SL1 is deployed in extracellular vesicles and preferentially transferred to\nintratumoral immune cells. Unlike other RNA agonists, RN7SL1 restricts development of\nmyeloid-derived suppressor cells and decreases TGFB expression. In dendritic cells, it\nfosters DC subsets with anti-viral and costimulatory features. Consequently, endogenous\neffector-memory CD8 T cells expand, while exhausted T cells contract. Armed with the\nability to activate endogenous immune responses, these CAR-T cells effectively reject\nsolid tumors and tumors with CAR antigen loss by drawing on our insights into tumor\nresistance mechanisms.
Author: Johnson, Lexus
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W7017768953
FWCI:
Cites: 290
Cited by:
Related to: 10